Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.

Autor: Om K; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Paquin-Proulx D; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Montero M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Peachman K; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Shen X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America., Wieczorek L; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Beck Z; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Weiner JA; Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, United States of America., Kim D; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Li Y; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Mdluli T; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Shubin Z; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Bryant C; EMMES, Rockville, Maryland, United States of America., Sharma V; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Tokarev A; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Dawson P; EMMES, Rockville, Maryland, United States of America., White Y; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Appelbe O; Department of Pharmaceutics, University of Washington, Seattle, Washington, United States of America., Klatt NR; Department of Pharmaceutics, University of Washington, Seattle, Washington, United States of America., Tovanabutra S; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Estes JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America., Matyas GR; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America., Alving CR; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America., Ackerman ME; Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, United States of America., Michael NL; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Polonis V; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Rolland M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Eller MA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America., Rao M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Bolton DL; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
Jazyk: angličtina
Zdroj: PLoS pathogens [PLoS Pathog] 2020 Sep 03; Vol. 16 (9), pp. e1008764. Date of Electronic Publication: 2020 Sep 03 (Print Publication: 2020).
DOI: 10.1371/journal.ppat.1008764
Abstrakt: To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env gp145 was evaluated in macaques with either aluminum (alum) or a novel liposomal monophosphoryl lipid A (MPLA) formulation adsorbed to alum, ALFA. Binding antibody responses were robust and comparable between arms, while antibody-dependent neutrophil and monocyte phagocytotic responses were greatly enhanced by ALFA. Per-exposure vaccine efficacy against heterologous tier 2 SHIV mucosal challenge was 90% in ALFA-adjuvanted males (P = 0.002), while alum conferred no protection. Half of the ALFA-adjuvanted males remained uninfected after the full challenge series, which spanned seven months after the last vaccination. Antibody-dependent monocyte and neutrophil phagocytic responses both strongly correlated with protection. Significant sex differences in infection risk were observed, with much lower infection rates in females than males. In humans, MPLA-liposome-alum adjuvanted gp120 also increased HIV-1-specific phagocytic responses relative to alum. Thus, next-generation liposome-based adjuvants can drive vaccine elicited antibody effector activity towards potent phagocytic responses in both macaques and humans and these responses correlate with protection. Future protein vaccination strategies aiming to improve functional humoral responses may benefit from such adjuvants.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje